Abstracts tagged "anti-TNF therapy"

Abstract Number: 630 • 2017 ACR/ARHP Annual Meeting
Effects of Intravenous Golimumab, an Anti-Tnfα Monoclonal Antibody, on Mental and Physical Functioning and Health-Related Quality of Life in Active Psoriatic Arthritis: 24-Week Results of a Phase 3 Trial
M. Elaine Husni¹, Arthur Kavanaugh², Eric K. H. Chan³, Nan Li⁴, Steven Peterson⁴, Elizabeth C. Hsia⁵, Lilianne Kim⁴, Kim Hung Lo⁴ and Diane D. Harrison⁴, ¹Rheumatology, Cleveland Clinic, Cleveland, OH, ²Medicine, University of California, San Diego, La Jolla, CA, ³Janssen Global Services, LLC, Raritan, NJ, ⁴Janssen Research & Development, LLC, Spring House, PA, ⁵Janssen Research & Development, LLC/University of Pennsylvania, Spring House/Philadelphia, PA
Background/Purpose: To evaluate physical and mental health functioning, health state, and health-related quality of life (HRQoL) in patients with active psoriatic arthritis (PsA) treated with…
Abstract Number: 1570 • 2017 ACR/ARHP Annual Meeting
Monocytes from Male Patients with Ankylosing Spondylitis Display Decreased Osteoclastogenesis and Decreased RANKL/OPG Ratio
Valéria F. Caparbo¹, Carla G.S. Saad¹, Julio C. B. Moraes², Artur J de Brum-Fernandes³ and Rosa M R Pereira⁴, ¹Rheumatology Division, Faculdade de Medicina da Universidade de Sao Paulo, Sao Paulo, Brazil, ²Rheumatology Division, Faculdade de Medicina da Universidade de Sao Paulo, São Paulo, Brazil, ³Rheumatology Division, Université de Sherbrooke, Rheumatology Division, Canada, Sherbrooke, QC, Canada, ⁴Rheumatology Division, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo, Brazil
Background/Purpose: Ankylosing Spondylitis (AS) is a chronic inflammatory disease characterized by new bone growth that leads to syndesmophyte formation and subsequent vertebral ankyloses, although AS…
Abstract Number: 638 • 2017 ACR/ARHP Annual Meeting
Are There Clinical Demographic or Subclinical Ultrasonographic Data That Can Predict Flare in Psoriatic Arthritis Patients during a Phase of Minimal Disease Activity after Spacing of Anti-TNF Blockers Injections?
Pierluigi Macchioni¹, Giovanni Ciancio², Gilda Sandri³, Alen Zabotti⁴, Luca Montaguti⁵, Gentiana Vukatana⁶, Fabio Mascella⁷, Donatella Chessa⁸, Elisa Verduci⁹, Marcello Govoni¹⁰, Amelia Spinella³, Francesca Zuliani¹¹, Marco Bruschi⁵, Nazzarena Malavolta¹² and Mariacristina Focherini⁷, ¹Rheumatology Unit, Arcispedale S Maria Nuova, IRCCS, Reggio Emilia, Italy, ²Rheumatology Unit, Department of Medical Sciences, University of Ferrara and Azienda Ospedaliera-Universitaria Sant’Anna - Ferrara (Italy), ferrara, Italy, ³Rheumatology Unit, University fo Modena & Reggio, Modena, Italy, ⁴Rheumatology Clinic, Department of Medical and Biological Sciences, Santa Maria della Misericordia" University Hospital, Udine, Italy, ⁵Dipartimento Internistico SS di Reumatologia, AUSL Romagna Ospedale Bufalini, Cesena, Italy, ⁶Rheumatology Unit, Department CardioThoracic Vascular, S.Orsola- Malpighi Hospital, Alma Mater Studiorum, Bologna, Bologna, Italy, ⁷Internal Medicine and Rheumatology, Ospedale Infermi Rimini, Rimini, Italy, ⁸Internal Medicine, Ospedale Paolo Dettori, Tempio Pausania, Italy, ⁹Rheumatology Unit, Arcispedale S. Maria Nuova, Reggio Emilia, Italy, ¹⁰Rheumatology Clinic, Department of Medical and Biological Sciences, University of Ferrara and Azienda Ospedaliera-Universitaria Sant’Anna - Ferrara (Italy), ferrara, Italy, ¹¹Rheumatology Unit, Department of Medical Sciences, Santa Maria della Misericordia" University Hospital, Udine, Italy, ¹²Policlinico S.Orsola-Malpighi, Azienda Ospedaliero-Universitaria of Bologna, Bologna, Italy
Background/Purpose: Tumour necrosis factor (TNF)-blocker tapering has been proposed for patients with psoriatic arthritis (PA) in clinical remission. To evaluate if there are clinical, demographic…
Abstract Number: 1825 • 2017 ACR/ARHP Annual Meeting
Comparative Analysis of Achievement of Individual Important Response Measured By DAS28dcrit in a Randomized Head-to-Head Trial of Tocilizumab Vs. Adalimumab in Active Rheumatoid Arthritis
Michaela Koehm¹, Michael Hofmann², Rasmus Lüthje², Matthew McIntosh³, Varghese Abraham³, Cem Gabay⁴, Arthur Kavanaugh⁵, Harald Burkhardt⁶ and Frank Behrens⁶, ¹Division of Rheumatology and Fraunhofer IME-Project-Group Translational Medicine and Pharmacology, Goethe University, Frankfurt/Main, Germany, ²Rheumatology, Chugai Pharma Europe Ltd., Frankfurt, Germany, ³Genentech, San Francisco, CA, ⁴SCQM, Geneva, Switzerland, Geneva, Switzerland, ⁵Medicine, University of California, San Diego, La Jolla, CA, ⁶Division of Rheumatology and Fraunhofer IME-Project-Group Translational Medicine and Pharmacology, Goethe University, Frankfurt, Germany
Background/Purpose: Fluctuations in disease activity due to short-term situational effects and measurement errors are important considerations for evaluation of individual clinically meaningful therapeutic response in…
Abstract Number: 1019 • 2017 ACR/ARHP Annual Meeting
Molecular Profiling of RA Patients Suggests a Differential Involvement of Adaptive and Innate Cell Populations in Response to Anti-TNF Treatment
Victor Farutin¹, Thomas Prod'homme¹, Kevin McConnell¹, Nathaniel Washburn¹, Patrick Halvey¹, Jamey Guess¹, Nur Sibel Gunay¹, Jan Hillson², Carol J. Etzel³, Katherine C. Saunders³, Dimitrios A. Pappas^3,4, Anthony Manning¹, Leona Ling¹ and Ishan Capila¹, ¹Research, Momenta Pharmaceuticals, Inc., Cambridge, MA, ²Clinical Research, Momenta Pharmaceuticals, Inc., Cambridge, MA, ³Corrona, LLC, Southborough, MA, ⁴Columbia University, New York, NY
Background/Purpose: Despite the success of anti-TNF therapies in RA, ~ 30 % of patients are non-responders. Several studies have focused on understanding the biology underlying…
Abstract Number: 1905 • 2017 ACR/ARHP Annual Meeting
Sustained Response Following Discontinuation of Methotrexate in Patients with Rheumatoid Arthritis Treated with Subcutaneous Tocilizumab: Results from a Randomized Controlled Trial
Joel Kremer¹, William F C Rigby², Nora Singer³, Christine Birchwood⁴, Darcy Gill⁴, William Reiss⁴, Jinglan Pei⁴ and Margaret Michalska⁴, ¹Albany Medical College, Albany, NY, ²Geisel School of Medicine at Dartmouth, Lebanon, NH, ³Case Western Reserve University School of Medicine, Cleveland, OH, ⁴Genentech, Inc., South San Francisco, CA
Background/Purpose: Although methotrexate (MTX) is often administered in combination with biologics for the treatment of rheumatoid arthritis (RA), it may be discontinued due to intolerance…
Abstract Number: 1049 • 2017 ACR/ARHP Annual Meeting
Heart Rate Variability Testing with Autonomic Nervous System Optimization: Could It Change the Course of Spending for Rheumatoid Arthritis Patients in the U.S.? an Exploratory Minimal Model Analysis
Marita Zimmermann¹, Elisabeth Vodicka², Andrew J Holman^3,4,5 and Louis P Garrison², ¹Constants in Global Health, University of Washington, Seattle, WA, ²Consultants in Global Health, University of Washington, Seattle, WA, ³Rheumatology, Pacific Rheumatology Associates Inc PS, Seattle, WA, ⁴Inmedix, Normandy Park, WA, ⁵Pacific Rheumatology Reseach, Seattle, WA
Background/Purpose: Autonomic nervous system (ANS) testing with heart rate variability (HRV) has been shown to predict 52-week anti-TNF therapeutic outcomes in rheumatoid arthritis (RA).1 HRV…
Abstract Number: 2449 • 2017 ACR/ARHP Annual Meeting
Comparative Effectiveness of Tocilizumab (TCZ) Monotherapy with Tumor Necrosis Factor Inhibitors (TNFi) in Combination with Varying Doses of Methotrexate (MTX) in Patients with Rheumatoid Arthritis
Leslie R Harrold¹, George W. Reed¹, Jennie Best², Steve Zlotnick², Gioia Persuitte³ and Joel Kremer⁴, ¹University of Massachusetts Medical School, Worcester, MA, ²Genentech, Inc., South San Francisco, CA, ³Corrona, LLC, Southborough, MA, ⁴Albany Medical College and The Center for Rheumatology, Albany, NY
Background/Purpose: Clinical studies have shown that the efficacy of TCZ monotherapy (TCZ mono) is superior to that of TNFi monotherapy and comparable to that of…
Abstract Number: 1057 • 2017 ACR/ARHP Annual Meeting
Budgetary Impact Analysis of Real-World Dosing Patterns in Matched Cohorts of Rheumatoid Arthritis Patients Treated with Infliximab or Golimumab Intravenous Anti-TNF Medications
Lorie A. Ellis¹, Elisabetta Malangone-Monaco², Helen Varker², Diana Stetsovsky³, Maureen Kubacki⁴, Raphael J. DeHoratius⁵ and Shelly Kafka⁴, ¹Janssen HECOR Immunology, Horsham, PA, ²Truven Health Analytics, Bethesda, MD, ³Truven Health Analytics, Philadelphia, PA, ⁴Janssen Scientific Affairs, LLC, Horsham, PA, ⁵Janssen Scientific Affairs, LLC/Sidney Kimmel School of Medicine, Thomas Jefferson University, Horsham/Philadelphia, PA
Background/Purpose: Infliximab (IFX) is more frequently selected than golimumab for intravenous use (GLM-IV) in patients with Rheumatoid Arthritis (RA) but differences in dosing and administration…
Abstract Number: 2451 • 2017 ACR/ARHP Annual Meeting
Rapid Onset of Response Observed with Certolizumab Pegol in Rheumatoid Arthritis Patients with Inadequate Response to Methotrexate: Efficacy and Safety Results of a Randomized, Double-Blind, Placebo-Controlled Phase 3 Study
Liqi Bi¹, Yuhui Li², Lan He³, Huji Xu⁴, Jieruo Gu⁵, Guochun Wang⁶, Zhiyi Zhang⁷, Yi Liu⁸, Marion Boehnlein⁹, Jochen Dunkel⁹, Jing Shao¹⁰, Kristina Harris¹¹ and Zhanguo Li¹², ¹China-Japan Union Hospital of Jilin University*, Changchun, China, ²Peking University People’s Hospital*, Beijing, China, ³The First Affiliated Hospital of Xi’an Jiaotong University, Xi'an, China, ⁴Shanghai Changzheng Hospital, Shanghai, China, ⁵Sun Yat-sen University – The Third Affiliated Hospital, Guangzhou, China, ⁶China-Japan Friendship Hospital, Beijing, China, ⁷The First Affiliated Hospital of Harbin Medical University, Harbin, China, ⁸West China Hospital, Sichuan University, Chengdu, China, ⁹UCB Pharma, Monheim, Germany, ¹⁰UCB Pharma, Tokyo, Japan, ¹¹UCB Pharma, Slough, United Kingdom, ¹²Peking University People's Hospital, Beijing, China
Background/Purpose: There are unmet needs for patients (pts) suffering from rheumatoid arthritis (RA) in China, where a limited number of anti-TNFs are available.1, 2 Certolizumab…
Abstract Number: 80 • 2017 Pediatric Rheumatology Symposium
Treatment of Blau Syndrome with Biologic Therapy: A Single Center Case Series of Seven Patients Over Two Decades
Jennifer Rammel¹, Patricia Rosillo¹, Tiphanie Vogel² and Marietta de Guzman³, ¹Department of Pediatrics, Division of Immunology, Allergy and Rheumatology, Baylor College of Medicine, Houston, TX, ²Department of Pediatrics, Division of Immunology, Allergy and Rheumatology and the Center for Human Immunology at Texas Children's Hospital., Baylor College of Medicine, Houston, TX, ³Department of Pediatrics, Division of Immunology, Allergy and Rheumatology, Baylor College of Medicine, Texas Children's Hospital, Houston, TX
Background/Purpose: Blau syndrome is a rare autoinflammatory granulomatous disease that presents with fever, arthritis, dermatitis and uveitis. It results from mutations in NOD2, an intracellular…
Abstract Number: 597 • 2016 ACR/ARHP Annual Meeting
Comparative Effectiveness of Different Anti-TNF Drugs As First Biological DMARD in RA: Results from the Nationwide Swedish Register 2010-2015
Thomas Frisell¹, Mats Dehlin², Daniela Di Giuseppe³, Nils Feltelius⁴, Alf Kastbom⁵, Carl Turesson⁶, Johan Askling⁷ and the ARTIS Study Group, ¹Clinical Epidemiology Unit, Department of Medicine, Karolinska Institutet, Stockholm, Sweden, ²Department of Rheumatology and Inflammation Research, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden, ³Clinical Epidemiology Unit, Dept. of Medicine, K2, Karolinska institutet, Stockholm, Sweden, ⁴Swedish Medical Products Agency, Uppsala, Sweden, ⁵Department of Clinical and Experimental Medicine, Rheumatology/AIR, Linköping, Sweden, ⁶Department of Rheumatology, Skåne University Hospital, Malmö, Sweden, ⁷Clinical Epidemiology Unit, Department of Medicine, Karolinska Institutet, Stockholm, Sweden, Stockholm, Sweden
Background/Purpose: Although evidence from randomized trials suggest similar efficacy and safety on a group level for the different anti-TNF drugs available for the treatment of…
Abstract Number: 947 • 2016 ACR/ARHP Annual Meeting
A Multi-Center, Open-Label Study to Assess the Pharmacokinetics, Efficacy and Safety of Certolizumab Pegol in Children and Adolescents with Moderately to Severely Active Polyarticular-Course Juvenile Idiopathic Arthritis: Week 24 Results
Hermine I. Brunner¹, Nicolino Ruperto², Vladimir Keltsev³, Ekaterina Alexeeva⁴, Carlos Abud-Mendoza⁵, Heinrike Schmeling⁶, María del Rocío Maldonado-Velázquez⁷, Nadina Rubio-Pérez⁸, Marina Stanislav⁹, Vyacheslav Chasnyk¹⁰, Diane Brown¹¹, Michael Henrickson¹, Daniel Kingsbury¹², C. Egla Rabinovich¹³, Andrew Zeft¹⁴, Earl Silverman¹⁵, Maggie Wang¹⁶, Philippa Charlton¹⁶, Rocio Lledo-Garcia¹⁷, Laura Shaughnessy¹⁶, Daniel J. Lovell¹ and Alberto Martini², ¹PRCSG, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ²PRINTO, Istituto Gaslini, Genoa, Italy, ³Togliatti City Clinical Hospital №5, Togliatti, Russian Federation, ⁴Children's Health of RAMS and IM Sechenov First Moscow State Medical University, Moscow, Russian Federation, ⁵Hospital Central & Facultad de Medicina, Universidad Autónoma de San Luis Potosí, San Luis Potosí, Mexico, ⁶Alberta Children's Hospital, University of Calgary, Calgary, AB, Canada, ⁷Hospital Infantil de Mexico Federico Gomez, Mexico City, Mexico, ⁸Universidad Autónoma de Nuevo León, Nuevo León, Mexico, ⁹Research Rheumatology Institute V.A. Nassonova, Moscow, Russia, ¹⁰St Petersburg State Pediatric Medical Academy, St Petersburg, Russian Federation, ¹¹Division of Rheumatology, Children's Hospital of Los Angeles and University of Southern California, Los Angeles, CA, ¹²Pediatric Rheumatology, Randall Children's Hospital at Legacy Emanuel, Portland, OR, ¹³Duke University Medical Center, Durham, NC, ¹⁴Cleveland Clinic, Pediatric Rheumatology, Cleveland, OH, ¹⁵Hospital for Sick Children, Toronto, ON, Canada, ¹⁶UCB Pharma, Raleigh, NC, ¹⁷UCB Pharma, Slough, United Kingdom
Background/Purpose: Juvenile idiopathic arthritis (JIA) often requires biologic medication to control polyarticular disease courses. This study assesses the pharmacokinetics (PK), efficacy and safety of certolizumab…
Abstract Number: 2250 • 2016 ACR/ARHP Annual Meeting
A Real World View of Rheumatoid Arthritis Patients Treated with Advanced Therapies: Comparing Patient Profiles and Outcomes
Laurent Chanroux and Fara Mboge, Therapy Watch, Research Partnership, London, United Kingdom
Background/Purpose: Advanced therapies including bDMARDs and tofacitinib have been shown to help control disease progression in rheumatoid arthritis (RA) and reduce joint damage. The aim…
Abstract Number: 3067 • 2016 ACR/ARHP Annual Meeting
Treatment Decisions Following Diagnosis of Cancer during TNFi Inhibitor Treatment in Patients with Rheumatoid Arthritis: Results from the BSRBR-RA
Katie Druce¹, Diederik Decock², Kath Watson¹, Deborah P.M. Symmons¹ and Kimme L. Hyrich¹, ¹Arthritis Research UK Centre for Epidemiology, The University of Manchester, Manchester, United Kingdom, ²KU Leuven Department of Development and Regeneration, Skeletal Biology and Engineering Research Center, Leuven, Belgium
Treatment Decisions Following Diagnosis of Cancer During TNFi inhibitor Treatment in Patients with Rheumatoid Arthritis: results from the BSRBR-RA Druce KL, De Cock D, Watson…

« Previous Page
1
…
6
7
8
9
10
…
29
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

ACR Abstract Embargo Policy

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until Saturday, November 11, 2023.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the abstract embargo policy, please contact the public relations department at [email protected].

Copyright Policy

View ACR Policies.